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Abstract
Background: The GAVI Alliance supported10-valent pneumococcal conjugate vaccine (PCV10) introduction in Kenya. We
estimated the cost-effectiveness of introducing either PCV10 or the13-valent vaccine (PCV13) from a societal perspective
and explored the incremental impact of including indirect vaccine effects.
Methods: The costs and effects of pneumococcal vaccination among infants born in Kenya in 2010 were assessed using a
decision analytic model comparing PCV10 or PCV13, in turn, with no vaccination. Direct vaccine effects were estimated as a
reduction in the incidence of pneumococcal meningitis, sepsis, bacteraemic pneumonia and non-bacteraemic pneumonia.
Pneumococcal disease incidence was extrapolated from a population-based hospital surveillance system in Kilifi and
adjustments were made for variable access to care across Kenya. We used vaccine efficacy estimates from a trial in The
Gambia and accounted for serotype distribution in Kilifi. We estimated indirect vaccine protection and serotype
replacement by extrapolating from the USA. Multivariable sensitivity analysis was conducted using Monte Carlo simulation.
We assumed a vaccine price of US$ 3.50 per dose.
Findings: The annual cost of delivering PCV10 was approximately US$14 million. We projected a 42.7% reduction in
pneumococcal disease episodes leading to a US$1.97 million reduction in treatment costs and a 6.1% reduction in
childhood mortality annually. In the base case analysis, costs per discounted DALY and per death averted by PCV10,
amounted to US$ 59 (95% CI 26–103) and US$ 1,958 (95% CI 866–3,425), respectively. PCV13 introduction improved the
cost-effectiveness ratios by approximately 20% and inclusion of indirect effects improved cost-effectiveness ratios by 43–
56%. The break-even prices for introduction of PCV10 and PCV13 are US$ 0.41 and 0.51, respectively.
Conclusions: Introducing either PCV10 or PCV13 in Kenya is highly cost-effective from a societal perspective. Indirect effects,
if they occur, would significantly improve the cost-effectiveness.
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Introduction
In the year 2008, approximately 8.8 million deaths occurred
worldwide in children less than five years and pneumococcal
disease caused an estimated 521,000 of these deaths. [1,2] Trials of
pneumococcal conjugate vaccines (PCV) conducted among infants
have shown significant efficacy against invasive pneumococcal
disease (IPD), [3,4,5,6] and by early 2010 PCV had been
introduced into routine immunization programmes in over 50
high- and middle-income countries. [7,8] The World Health
Organization had also recommended the introduction of PCV
into the immunization schedules in developing countries with high
background rates of childhood mortality. [9].
In 2011, the GAVI Alliance received pledges for sufficient
funding to support introduction of PCV into all countries with
Gross National Income per capita below US$ 1,520. [10] Kenya
introduced universal infant vaccination with 10-valent PCV in
February 2011 with financial support from the GAVI Alliance.
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[11] Published country-specific estimates of the cost-effectiveness
of PCV are scarce for African countries. [12,13,14] The existing
studies do not include indirect effects of pneumococcal vaccina-
tion, and most adopt a narrow health provider perspective. Some
international groups have produced global models, largely based
on variations in infant mortality. [15] Convincing analyses of cost-
effectiveness from developing countries require local data on
incidence and serotype distributions and effectiveness estimates
that go beyond mortality. [16].
In this economic evaluation we use Kenyan data on both
treatment costs and pneumococcal disease incidence by syndrome
and serotypes together with African evidence of vaccine efficacy to
estimate the cost-effectiveness of delivering PCV10 in routine
immunization services in Kenya. We include the vaccine impact
against both morbidity and mortality and also explore the
incremental benefits of incorporating indirect effects and of
switching to 13-valent vaccine (PCV13).
PCV10 is currently available to Kenya at a cost of $3.50 per
dose, which is being co-financed by the GAVI Alliance and the
Kenyan government for a 10-year period. [17] Donor funds,
availed under the Advance Market Commitment (AMC), are
being used to pay an extra $3.50 per dose for approximately 20%
of all vaccine doses purchased during this period. [18] At the end
of the co-financing period the government will take over the full
cost of the vaccine. The purpose of this cost-effectiveness analysis is
to assist policy makers in Kenya to plan beyond the co-financing
period. The study may also assist other countries with similar
vaccine costs and pneumococcal disease patterns, and inform
funding decisions of international vaccine donors.
Methods
The analysis was conducted from a societal perspective
considering both medical and non-medical costs and productivity
losses. A static decision analytic model (as opposed to dynamic
disease transmission model) using aggregate-level data was
employed in calculating health benefits, costs and incremental
cost-effectiveness of vaccinating all infants born in Kenya in 2010
at current vaccination coverage. We converted all costs to 2010
US$ using the GDP deflator. [19].
The base case analysis compared the discounted (3% per year)
costs and effects of universal PCV vaccination to those associated
with no PCV introduction and included only direct vaccine effects.
We assigned probability values to all costs and events and
calculated the expected values of each decision option. The
assigned probability values were identified from a variety of data
sources, including published literature identified through struc-
tured searches of PubMed, reviewing relevant health ministry’s
records, and expert opinion where data were unavailable from the
first two sources (Table 1).
Disease Incidence
We classified pneumococcal disease into invasive (IPD) and
non-invasive disease. IPD was defined by the isolation of S.
pneumoniae from blood, cerebrospinal fluid (CSF) or pleural fluid.
We sub-classified IPD into three syndromes; meningitis, sepsis,
and bacteraemic pneumonia, and included only one non-invasive
pneumococcal syndrome; non-bacteraemic pneumonia. The
possible outcomes from sepsis, bacteraemic- and non-bacteraemic
pneumonia are death or survival with complete recovery while for
meningitis they are death, survival with complete recovery or
survival with sequelae.
Hospital IPD incidence rates were calculated using the results of
paediatric inpatient surveillance from Kilifi District Hospital,
Kenya. [20] All children admitted to this hospital undergo blood
cultures on admission, and those meeting specific criteria undergo
CSF or pleural fluid cultures. [21] The hospital is situated at the
centre of the Kilifi Health and Demographic Surveillance System
(KHDSS), which covers an area of 891 km2 and re-enumerates a
population of about 250,000 people three times a year through
household visits. Computer systems at KDH link paediatric
admissions and microbiological results to the population register of
the KHDSS. The hospitalised incidence is given each year as the
number of cases of IPD residing within the KHDSS divided by the
mid-year population of the KHDSS. [21] Data from 7 years
(2003–2009) were used to estimate mean annual rates. Since
hospital-based surveillance underestimates the true burden of
pneumonia and meningitis by 45% and 30% we adjusted the
incidence rates, [22] dividing them by the proportion of children
who access hospital care. These proportions were derived from a
Ugandan study of health seeking behaviour (Table 1). [23].
We divided the IPD incidence into fractions attributable to
meningitis, sepsis and bacteraemic pneumonia on the basis of
clinical data from KDH. Meningitis was defined as positive CSF
or blood culture and CSF white cell count $506106 cells/L or a
ratio of CSF glucose to plasma glucose less than 0.1. Presentation
with fast breathing plus a history of either cough or difficult
breathing was required for a pneumonia diagnosis, chest
indrawing was required for severe pneumonia and one or more
of hypoxia, cyanosis, inability to drink, prostration or convulsions
for very severe pneumonia. IPD cases not meeting meningitis or
pneumonia criteria above were defined as sepsis. [24] We
estimated the incidence of non-bacteraemic pneumococcal pneu-
monia preventable by vaccination by extrapolating results of the
vaccine efficacy trial in The Gambia: in this trial the vaccine-
preventable burden of radiologically-confirmed pneumonia was
7.5 times greater than the vaccine-preventable burden of IPD. [4]
Therefore, to derive the incidence rate of non-bacteraemic
pneumococcal pneumonia we multiplied the observed IPD
incidence in Kilifi by 7.5 to estimate the incidence of radiolog-
ically-confirmed pneumococcal pneumonia and then subtracted
the reported incidence of bacteraemic pneumococcal pneumonia
to avoid double counting.
We used the efficacy estimates of PCV9 from a trial in The
Gambia because this setting resembles Kenya epidemiologically.
[4] Following the criteria of non-inferiority of immunogenicity
used by the regulatory agencies for licensing higher valent
vaccines, [25] we assumed that the efficacy of additional antigens
in the 10- and 13-valent PCV against their target serotypes was
equal to that in the baseline 9-valent PCV. To project the number
of cases preventable in each year of age we multiplied the vaccine
efficacy against IPD of serotypes in the vaccine in The Gambia
trial (92% for meningitis or sepsis, 77% for bacteraemic and non-
bacteraemic pneumonia), [4] with the number of cases that were
estimated to have disease caused by serotypes contained in the
PCV10 or PCV13 vaccine, and multiplied this by immunization
coverage. The proportion of IPD that was caused by serotypes in
each of the two vaccines was estimated for each year of age from
215 episodes of IPD reported among children under five in Kilifi
District Hospital between 2003 and 2009.
Disability Adjusted Life Years (DALYs) Estimates
The DALYs averted as a result of pneumococcal vaccination
were calculated using the formula recommended by Murray et al.
[26] The calculations incorporated age weights (0.04), and
discounting (0.03). The disability weights were 0.28 for bacterae-
mic- and non-bacteraemic pneumonia and 0.616 for meningitis.
[26] Due to the absence of standard disability weights for
Infant Pneumococcal Vaccination in Kenya
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Table 1. Parameters used in the base case analysis for pneumococcal vaccination in Kenyan infants born in 2010 *BCV- Base case
value.
Parameter Base case Reference Statistical distribution Source
IPD incidence (per 105 child-years)
Meningitis
0–11 months 48.3 Kilifi HDSS Poisson (48.3) Kilifi HDSS
12–23 months 22.4 Poisson (22.4)
24–59 months 5.0 Poisson (5)
Sepsis
0–11 months 27.4 Kilifi HDSS Poisson (27.4) Kilifi HDSS
12–23 months 27.2 Poisson (27.2)
24–59 months 13.4 Poisson (13.4)
Bacteraemic pneumonia
0–11 months 74.0 Kilifi HDSS Poisson(74) Kilifi HDSS
12–23 months 41.6 Poisson(41.6)
24–59 months 17.8 Poisson(17.8)
Non-bacteraemic pneumonia
0–11 months 972.9 Extrapolation from
Cutts [4]
NA Extrapolation from Cutts et al
12–23 months 592.9 NA
24–59 months 235.4 NA
Vaccination
PCV9 efficacy against serotype specific disease
Meningitis 92% Cutts [4] Beta(92,8) Cutts et al
Sepsis 92% Beta(92,8)
Bacteraemic pneumonia 77% Beta(77,23)
Non-bacteraemic pneumonia 77% Extrapolated from
Cutts [4]
Beta(77,23) Extrapolation from Cutts et al
Access to healthcare
Outpatient care 37% Kallander [23] Beta (16,28) Kallander et al
Inpatient hospital care 40% Beta(18,26)
Health outcomes
Major post discharge meningitis sequelae 25% Edmond [27] Beta (25,75) Edmond et al
Case fatality with hospital care
IPD (sepsis, bacteraemic pneumonia) 28.2% Berkley, [41] expert
opinion
Beta (28,72) Berkley et al, expert opinion
Non-bacteraemic pneumonia 5.7% Berkley, [41] expert
opinion
Beta (6,94) Berkley et al, expert opinion
Case fatality without hospital care
Meningitis 97% Expert opinion Beta (97,3) Expert opinion
Sepsis and bacteraemic pneumonia 50% Beta (4,4)
Non-bacteraemic pneumonia 12% Beta (12,88)
Inpatient treatment costs
Meningitis $357.74 Ayieko [28] Gamma (4,19) Ayieko et al
Sepsis or pneumonia $74.64 Gamma (1,314)
Outpatient treatment cost
Childhood fever $2.74 Larson [29] NA Larson et al
Discounting
Costs = 0%; effects = 0% NA Assumption NA
Costs = 3%; effects = 3% NA Assumption NA
NA- Not applicable.
doi:10.1371/journal.pone.0067324.t001
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pneumococcal sepsis we used the pneumonia disability weight. For
lifelong meningitis sequelae, we assumed that 25% of all PCV
meningitis cases in Africa develop major neurological deficits, [27]
and applied the disability weight for motor deficits (0.334) to these
episodes. [26].
Vaccine Programme
Infant vaccines are delivered through the Kenya Expanded
Programme on Immunization (KEPI) currently being run by the
Ministry of Public Health and Sanitation’s (MOPHS) Division of
Vaccines and Immunizations (DVI). Prior to PCV introduction,
seven antigens were routinely delivered during infant immuniza-
tion thorough KEPI, namely birth BCG, oral polio vaccine (birth,
4, 6 and 10 weeks), DPT plus Hepatitis B antigen and Haemophilus
influenzae type B (administered as a combined pentavalent vaccine
at 4, 6, and 10 weeks). Introduction of pneumococcal vaccine (also
administered at 4, 6, and 10 weeks) required strengthening of
existing immunization services. In the present analysis capital costs
for Expanded Programme on Immunization (EPI) were confined
to additional investments in cold chain storage capacity at the
national and regional EPI stores across the country. These
expenditure data were obtained from DVI and from plans for
cold chain procurement specified in the country application for
GAVI Alliance support. Initially, Kenya planned to introduce
PCV7, which requires 59.9 cm3 of storage volume per dose and
the cold chain was expanded to accommodate this. A fraction of
this substantial cold chain investment was allocated to programme
cost estimates for the two PCV formulations in proportion to their
smaller storage volumes, being 4.8 cm3 for PCV10 and 12.0 cm3
for PCV13.
Recurrent costs included vaccines and supply procurement. The
current three-dose infant PCV schedule was incorporated in the
model and a vaccine wastage rate of 15% applied for PCV and a
wastage of 5% for injection and safety equipments. We estimated
the price of a single dose of pneumococcal vaccine at US$ 3.50,
which is the maximum price the Kenya Government could pay
under the AMC contract, which is effective until 2020. Vaccine
wastage (15%), freight (2%), and vaccine administration charges
were added to the costs per dose. Additional analyses were
undertaken to capture the government perspective by applying the
co-financing payment of US$0.20 per dose currently paid by the
Kenyan government under the GAVI Alliance policy.
Health-care Seeking Behaviour
There are widespread disparities in health care seeking
behaviour in developing countries. Findings of a recent verbal
autopsy study for fatal pneumonia estimated that 37% and 40% of
childhood pneumonia cases access outpatient care and inpatient
hospital care, respectively and 23% of children do not reach care.
[23] Such findings have important implications for the analysis
approach we adopted. For example, there is significant potential
for underestimating the true pneumococcal disease incidence
because the modelled estimates of pneumococcal disease burden
are derived from hospital based surveillance yet over 45% of
pneumonia cases and 30% of meningitis cases are missed by
hospital surveillance because of difficulties in accessing hospital
care. [22] We assumed 23% of children do not access care and
37% access out-patient care only as reported in verbal autopsy
studies. [23] We presented the uncertainty in the access to care
parameters by a beta a,bð Þ distribution (Table 1). Further,
children accessing formal healthcare were assigned lower case
fatality rates [beta a,bð Þ] for the different pneumococcal disease
syndromes compared to those who failed to reach care (Table 1).
Pneumococcal Disease Costs
The average cost of inpatient treatment were obtained from a
study of hospital resource utilization among 572 paediatric
admission at 7 different hospitals in Kenya. [28] The societal cost
of treating an episode of inpatient pneumonia or sepsis is
US$74.64 (SD 37.23) and an acute meningitis episode cost
US$357.74 (SD 335.12) (Table 1). These included direct medical
costs, the opportunity cost of caretaker time and household out-of-
pocket costs. Outpatient visit costs were obtained from a study on
the cost of treating childhood fevers in Kenya. [29]. The costs of
treating meningitis sequelae were excluded from the analysis.
Sensitivity Analysis
Probabilistic sensitivity analysis was used to account for
parameter uncertainty by specifying variables as distributions
and conducting 10 000 Monte Carlo simulations using Crystal
BallH software (Decisioneering, USA). The stochastic variables
identified in the model along with their distributions are presented
in Table 1. Results of sensitivity analysis were presented as
contribution to variance showing the percentage of variance in the
cost effectiveness estimates contributed by each assumption. The
contribution to variance is calculated in Crystal Ball by squaring
the rank correlation coefficients (between every assumption and
every forecast of cost effectiveness while simulation is running) and
normalising them to 100%. [30] During simulations the propor-
tions of patients accessing care and pneumococcal case fatality
rates were sampled from beta distributions and a Poisson
distribution was applied to pneumococcal disease incidence.
Conversely, costs were sampled from log-normal distributions.
Prediction intervals around the incremental CER were derived
from 10 000 Monte Carlo simulations. To incorporate indirect
effects we included additional parameters for both herd immunity
and serotype replacement. These modifications to the base case
model allowed us to assume a ‘‘mature’’ vaccination programme
in which indirect effects are established and to model costs and
effects for the entire Kenyan population. In the analysis of the
entire population, adult age group differences in pneumococcal
disease incidence and serotype coverage were accounted for by
dividing the population into strata (5–12, 13 to 54, 55 to 64 and
$65 years).
We projected the magnitude of indirect protection using
effectiveness data from the USA following the introduction of
PCV7 into the routine vaccination schedule. The magnitude of
indirect effects is heterogeneous across different countries, [31]
however, we selected these data because the population under
surveillance is large and the duration of surveillance is relatively
long. In the USA cases of IPD among children aged ,5 years
declined by 93.6% between 1999–2003 and the vaccine’s direct
effect accounted for a 63.9% reduction (vaccine efficacy6immu-
nization coverage) in disease burden. [32] The residual reduction
(93.9–63.9 = 30%) was caused by indirect protection. We defined
the indirect vaccine effectiveness as the proportion of cases of
vaccine-type (VT) disease that are not prevented by direct vaccine
effects in different age groups but are, however, prevented by
indirect vaccine effects. Given the direct vaccine effectiveness
estimate above (63.9%) the proportion of cases of VT disease not
prevented by the direct effect is 36.1% (i.e. 1–0.639) and the
indirect vaccine effectiveness is 83.1% (i.e. 0.30040.361). We thus
multiplied the number of VT cases remaining, after applying
direct protection from PCV10 vaccination, with 83.1% to estimate
the additional effect of indirect protection and undertook a
probabilistic sensitivity analysis within the range 40% to 100%.
We accounted for the negative effect of serotype replacement
disease using the same data from the USA. [33] In this
Infant Pneumococcal Vaccination in Kenya
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surveillance, children aged,5 years were 1.21 times more likely to
get non-vaccine type disease after PCV introduction. As there is
considerable heterogeneity in the magnitude of serotype replace-
ment disease, geographically we set ranges of 1.0 and 2.4 around
this parameter representing settings where no replacement disease
occurs and those with very high rates of replacement disease. [31].
Results
Disease Impact
A total of 1,407,000 infants born in Kenya in 2010 contributed
6,680,436 child-years of observation during the first five years of
life. The model projects a 42.7% reduction in childhood IPD
episodes from 96,387 to 55,197 following PCV10 introduction
(Table 2). Without PCV vaccination a total of 104,118 all-cause
child deaths were projected during follow up based on current
under-five mortality rate of 74 deaths per 1,000 births. The model
estimated that 14,412 (13.8%) of these deaths were attributable to
pneumococcal disease and PCV10 directly prevented 6,358 (6.1%)
childhood deaths. The impact of pneumococcal vaccination on
mortality caused by meningitis, sepsis, bacteraemic pneumonia
and non bacteraemic pneumonia are presented in Table 2.
Incremental Costs
Pneumococcal vaccine costs amount to US$ 13,662,205
annually (Table 2). The largest cold chain investments were two
cold rooms installed at the national level and three cold rooms at
the regional level, at a total cost of US$ 305,000, as well as 800
refrigerators for the lower storage levels purchased for
US$1,205,750 (Table 3). The two-dose vial presentation of 10
valent vaccines only requires a fraction of this capacity (Table 3)
and therefore incurs only a fraction of cold chain expansion costs.
Annual treatment cost averted amounted to US$ 1,958,907
following PCV10 introduction and US$2,397,906 with PCV13
(Table 4).
Cost-effectiveness
In the PCV10 base case analysis, assuming no indirect effects, a
3% discount rate and a price of US$ 3.50 per dose, the cost
effectiveness ratio for PCV10 versus status quo was US$59 (95%
CI, 26–103) per DALY averted, US$ 300 (95% CI, 145–488) per
case averted and US$ 1,958 (95% CI, 866–3,425) per death
averted (Table 4). Working with the same assumptions, cost
effectiveness of PCV13 versus status quo was US$ 47 (95% CI, 20–
83), US$ 238 (95% CI, 110–390) and US$ 1,558 (95% CI, 665–
2,764) per DALY, case and death averted, respectively. The non-
discounted estimates of base case vaccine cost effectiveness for
both PCV10 and PCV13 are presented as additional material
(Table S1).
The Kenya Government currently pays $0.20 per dose under a
co-financing arrangement with GAVI. From the Government
perspective, introduction of either PCV10 or PCV13 is cost
saving. The break-even prices for PCV10 and PCV13 are US$
0.41 and US$ 0.51, respectively. Accounting for vaccine indirect
effects increases the break-even prices to US$ 0.72 for PCV10 and
US$ 0.87 for PCV13.
Sensitivity Analysis
The cost effectiveness ratios were robust to changes in most of
the variables included in the sensitivity analysis providing strong
evidence that pneumococcal vaccination would be cost effective.
The results of the probabilistic sensitivity analysis are presented in
Figure 1. In the base case analysis three factors contributed
approximately 94% of the total variance in costs per DALY
averted. Vaccine price per dose explained approximately half of
Table 2. Estimated cost and disease impact of pneumococcal vaccination with PCV10 and PCV13 in Kenyan infants born in 2010.
Without PCV10 PCV10 Introduction PCV13 Introduction
Pneumococcal disease episodes*
Meningitis 3,180 1,659 1,308
Sepsis 3,449 1,626 1,229
Bacteraemic pneumonia 6,221 3,602 3,027
Non-bacteraemic pneumonia 83,537 48,310 40,497
Total disease episodes 96,387 55,197 46,061
Total reduction in disease episodes – 41,190 50,326
Pneumococcal deaths*
Meningitis 2,275 1,186 934
Sepsis 1,448 684 576
Bacteraemic pneumonia 2,612 1,513 1,270
Non-bacteraemic pneumonia 8,077 4,671 3,916
Total pneumococcal deaths 14,412 8,054 6,636
Total reduction in pneumococcal deaths – 6,358 7,776
Pneumococcal vaccination costs (2010 US$)
Pneumococcal vaccine procurement cost – $13,662,205 $13,662,205
Injection equipment cost (syringes, safety boxes) – $360,306 $360,306
Annualized cold chain expansion costs – $14,758 $70,714
Total costs of vaccination – $14,037,268 $14,093,224
*The number of pneumococcal deaths and episodes are non-discounted.
doi:10.1371/journal.pone.0067324.t002
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the variance in vaccine cost effectiveness. Access to care
parameters accounted for most of the remaining variance
accounting for 31% of the total variation while assumptions on
case fatality of various pneumococcal syndromes also explained a
substantial proportion (11%) of reported variation in cost
effectiveness. These values are important considering that case
fatality rates are significantly higher among children who do not
reach formal health care compared to those who do.
Assuming that indirect effects are similar to those observed in
USA, pneumococcal vaccination with PCV10 and PCV13 would
cost US$32 (14–55) and US$ 25 (10–44) per DALY averted,
respectively, representing a 56% improvement in cost effective-
ness. The cost per case averted reduces to US$ 189 (85–320) and
US$ 147 (62–258) for PCV10 and PCV13, respectively (Table 4).
Under these assumptions it would cost US$ 1,158 (505–2,025) and
US$ 888 (366–1,597) to avert a single pneumococcal death with
PCV10 and PCV13 (48% improvement in cost effectiveness).
Discussion
This study conducted around the period of PCV introduction in
several African countries, and shortly after PCV introduction in
Kenya, shows that pneumococcal vaccination is highly cost-
effective using Kenya’s current GDP per capita of US$775 as a
benchmark. [34] At a cost of US$ 59 ($Int 114) per DALY averted
pneumococcal vaccination compares favourably with the most cost
effective packages of child health interventions delivered at high
coverage in sub-Saharan Africa. Other cost-effective interventions
include micronutrient fortification ($Int 19 per DALY), and the
incremental inclusion of measles vaccination ($Int 29–58 at
different population coverages), pneumonia case management
($Int 73), micronutrient supplementation ($Int 85) and oral
rehydration therapy ($Int 106–243 at different population
coverages). [35] Data from this region indicates that various
HIV/AIDS antiretroviral regimens cost between $Int500 and
$Int5000 per DALY averted. [36].
The projected cost effectiveness of pneumococcal vaccination in
our study ($Int 114) is slightly higher than the estimates of $Int 100
and $Int 69 per DALY averted among children in GAVI eligible
countries and the countries with Under-5 mortality rates of 100–
150 per 1000 births, respectively. [15] These differences are not
significant because the international economic evaluation in GAVI
eligible countries used a vaccine price of $Int 5 compared with a
value of approximately $Int 7 (US$3.50) in the present study. In
contrast to the international study, [15] our model estimated the
epidemiological burden of pneumococcal disease directly from
country-specific data. We projected that 14,412 deaths occur
during the first 5 years of life among infants born in Kenya during
2010 due to pneumococcal disease. This figure is similar to the
estimate of 16,433 deaths among Kenyan children under 5 years
during the year 2000 reported in the Pneumococcal Global
Burden of Disease (GBD) Study, which relied heavily on published
data from Kilifi. [37] The reported improvement in child health
indices during the ten-year period between the studies could
explain the similarity in mortality despite the annual increase in
the size of the Kenyan birth cohort. At the level of morbidity, the
GBD study estimated an annual burden of 235,522 cases per year,
substantially greater than the 96,387 estimated in our -analysis; the
bulk of these differences lies in the category of non-bacteraemic
pneumonia for which it is difficult to obtain consistent syndromic
data but the comparison illustrates the essentially conservative
nature of the parameters selected for our analysis. [38,39].
Of significance among the assumptions made in the base case
analysis is the exclusion of indirect vaccine effects, failure to
account for transmission dynamics of pneumococcal disease.
However, inclusion of indirect effects in the sensitivity-analysis
resulted in an approximately 2-fold improvement in cost-
effectiveness ratios. In this sensitivity analysis we modelled the
positive impact of herd effect and the negative impact of
replacement disease, but did not model further positive gains
resulting from, for example, reduced antibiotic resistance. It is
likely that the cost-effectiveness ratios presented in the indirect
effects scenarios still represent conservative estimates. [16]
However, the magnitude of indirect effects in our setting remains
uncertain and further studies will be required to refine the
estimates after these indirect effects are established.
Table 3. Cold chain storage costs incurred by the Kenyan government during 2008 in preparation for pneumococcal vaccine
introduction.
Quantity
Total annualised
cost* ($)
Cost allocated to
PCV10 ($)
Cost allocated to
PCV13($)
National vaccine store
Cold rooms 2 14,302 1,150 5,510
Stand by generators 2 2829 227 1,090
Regional level
Cold rooms 3 21,453 1,725 8,265
District stores
District storage refrigerators 200 35,338 2,841 13,614
Immunizing facilities
Immunizing facility refrigerators 600 106,013 8,524 40,843
Vaccine carriers 1,000 991 80 382
Cold boxes 50 2,622 211 1,010
Total costs 183,548 14,758 70,714
Cost per child born in 2010 0.13 0.010 0.05
Cost per fully immunized child 0.16 0.013 0.06
doi:10.1371/journal.pone.0067324.t003
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The cost-effectiveness model indicates that using PCV13
instead of PCV10 would reduce the cost per DALY averted
from USD 59 to USD 47 (Table 4). This differential is entirely
a function of the relative frequency in Kenya of serotypes 3, 6A
and 19A, which are contained in PCV13 alone, compared to
the 10 serotypes common to both vaccines. There is no
information available on the relative effectiveness of each
vaccine against vaccine-type disease nor the relative capacity
of each vaccine to cause indirect protection or serotype
replacement disease. Furthermore, the model does not incorpo-
rate potential protective effects of the Protein D carrier, which
is unique to PCV10, against H. influenzae disease. Until further
epidemiological information becomes available the relative
merits of the two formulations will remain uncertain.
The findings of the probabilistic sensitivity analysis confirm
the over-riding importance of vaccine price, [15] and access to
care estimates in cost-effectiveness analysis and particularly for
access to care this sensitivity analysis agrees with previously
published epidemiological models of disease burden based on
hospital data.16 We incorporated the impact of access to care
on pneumococcal disease outcome by assigning poorer outcomes
(higher case fatality rates) to children with limited access care
while those accessing care had lower case fatalities. However,
the assumption of similar vaccination coverage in children with
and without access to hospital care is a potential shortcoming of
our analysis. Our assumption is supported by studies conducted
in rural African settings that show that distance to hospital (as a
proxy of access to care) does not affect vaccination coverage in
children within the hospital’s catchment area. [40] Despite this
evidence, in the scenario that children with low access to care
also have lower vaccination coverage which is particularly likely
in settings with lower health facility density it is plausible that
vaccine cost effectiveness will be less favorable. The magnitude
of decline in cost effectiveness is likely to be insignificant in
areas with functional immunization programmes.
The uncertainty that derives from inaccuracy in access to
care parameter indicates the priority for accurate and repro-
ducible field data on health seeking behaviour in the region.
Beyond the base case analysis, the parameters for herd
protection and replacement disease required for models
incorporating pneumococcal disease transmission dynamics are
a source of considerable uncertainty and will remain so until
these effects have been quantified in a developing world setting.
Our objective was to provide an analysis that would inform
decision makers in Kenya, and other similar developing countries.
The analysis suggests that introduction of PCV10 in Kenya will
reduce the number of cases of pneumococcal disease by 41,190
and reduce childhood mortality by 6.1%. Our base-case estimate
of US$ 59 per DALY averted means that PCV is a highly cost-
effective intervention whether compared against the benchmark of
per capita GDP or against other competing health interventions.
Furthermore, this is a highly conservative estimate and realistic
adjustment for indirect vaccine effects throughout the whole
population improves the cost-effectiveness ratios by approximately
56% (US$ 32 per DALY averted). This analysis provides strong
support for the economic case for the introduction and mainte-
nance of the pneumococcal conjugate vaccine programme in
Kenya and in other developing countries with similar economic
and epidemiological profiles.
Figure 1. Percentage contribution to variance of uncertain parameters in base case analysis (cost per DALY averted for PCV10).
doi:10.1371/journal.pone.0067324.g001
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